February 2003
Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p3
Trade Publication
Reports on the official notice received by Aphton Corp. from the Therapeutic Goods Administration granting its gastrin G17DT Immunogen Orphan-Drug status for the treatment of both gastric cancer and pancreatic cancer.


Related Articles

  • Aphton reports positive results for gastric cancer therapy.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p7 

    Reports on Aphton Corp.'s launch of final results from its phase I single-arm clinical trial of G17DT in combination therapy with Cisplatin and 5-FU in patients with advanced gastric cancer. Mechanism of action of Aphton's anti-gastrin targeted immunotherapy; Primary end-point of the trial.

  • Aphton, Pasteur Merieux form marketing alliance.  // Chemical Market Reporter;2/24/97, Vol. 251 Issue 8, p27 

    Reports on the strategic alliance between Aphton Corp. and Pasteur Merieux Connought for Aphton's immunotherapeutic product Gastrimmune, a drug for all human cancer applications.

  • Colorectal Cancer News Headlines January 15, 2004--February 14, 2004.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p6 

    Presents news updates concerning colorectal cancer treatment compiled as of February 14, 2004. Immunomedics' report of phase II colorectal cancer therapy data at a cancer symposium; Aphton's disclosure of positive results for its gastric cancer therapy; Cyprotex's provision of support to cancer...

  • Pancreatic Cancer Update.  // PharmaWatch: Cancer;Apr2005, Vol. 4 Issue 4, p19 

    The article presents updates on several clinical trials related to pancreatic cancer. The shares of Aphton Corp. has declined after its investigation immunotherapy, Insegia, failed to improve overall survival in patients with pancreatic cancer in a phase III study. A patient enrollment is...

  • Breast Cancer Update.  // PharmaWatch: Cancer;August 2005, Vol. 4 Issue 8, p6 

    The article presents information on various developments related to breast cancer. Arimidex, AstraZeneca Pharmaceuticals' breast cancer drug, is set to become a more widely used treatment in Great Britain after regulators approved its use for postmenopausal women suffering from a type of breast...

  • APHTON DISCOVERS ROLE OF GASTRIN IN LUNG CANCERS.  // Biotech Business;Sep2001, Vol. 14 Issue 9, p6 

    Reports on the findings by Aphton Corporation regarding the role of gastrin receptors in lung cancers.

  • Gastrin 17 vaccine – Aphton: Anti-gastrin 17 immunogen, G17DT.  // BioDrugs;2003, Vol. 17 Issue 3, p223 

    Aphton is developing an anti-gastrin vaccine [Anti-gastrin 17 immunogen, G17DT, Gastrimmune[sup ®]], which neutralises the gastrin 17 hormone and the Gly-G17 hormone. Gastrin 17 is a growth factor for pancreatic, stomach and colorectal cancers, and a potent stimulator of gastric acid...

  • Cancer Vaccines Advance To Commercialization, But Challenges Lie Ahead in the Road to Success. Mirasol, Feliza // Chemical Market Reporter;6/7/2004, Vol. 265 Issue 23, pFR10 

    Reports on the state of the cancer vaccines field as of June 2004. Tentative market for cancer vaccines; Lack of industry benchmarks; Activities and plans of cancer vaccine producers including Antigenics Inc., Aphton Corp., Biomira Inc. Cell Genesys Inc. and Genitope Corp.

  • Aphton presents encouraging phase III clinical trial results of G17DT.  // PharmaWatch: Cancer;July 2004, Vol. 3 Issue 7, p19 

    Reports on positive results presented by Aphton Corp. from its phase III clinical trial testing G17DT as a monotherapy for patients with advanced pancreatic cancer who are unable to tolerate or unwilling to take chemotherapy. Group-sequential pancreatic cancer trial aimed at comparing overall...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics